Clinical trial
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
NCT04697446
Study timeline
Study start (actual)2020-12-01Date precision: day
Registry last updated2021-08-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
RET-fusion Non Small Cell Lung Cancerunresolved
Lung Neoplasmunresolved
Carcinoma, Non-Small-Cell Lungunresolved
Respiratory Tract Neoplasmsunresolved
Thoracic Neoplasmsunresolved
Neoplasms by Siteunresolved
Neoplasmsunresolved
Lung Diseasesunresolved
Respiratory Tract Diseasesunresolved
Carcinoma, Bronchogenicunresolved
Bronchial Diseasesunresolved
Head and Neck Neoplasmsunresolved
Carcinomaunresolved
Neoplasms by Histologic Typeunresolved
Neoplasms, Germ Cell and Embryonalunresolved
Neoplasms, Nerve Tissueunresolved
Metastatic Non Small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
Blueprint Medicines Corporationlead sponsor
Analysis Group, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04697446 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.